Anadrol

Intro

Oxymetholone — sold as Anadrol-50 since its FDA approval in 1972 — is a 17α-alkylated oral anabolic-androgenic steroid derived from dihydrotestosterone (DHT).

Despite its DHT lineage, oxymetholone behaves differently from most DHT derivatives in several critical ways that define its place in performance enhancement: it is not a substrate for 5α-reductase (so it doesn't amplify further in androgen-sensitive tissues), its primary anabolic mechanism is non-androgen-receptor-mediated (enabling genuine mechanistic synergy in multi-drug stacks), and it produces significant estrogenic effects through direct estrogen receptor agonism — not aromatization — rendering aromatase inhibitors ineffective against its estrogenic side effects.

The compound was originally developed by Syntex Pharmaceuticals and approved by the FDA in 1960 for aplastic anemia, Fanconi's anemia, and later HIV wasting. Its erythropoietic properties — stimulating red blood cell production via EPO upregulation — were therapeutically valuable, though the same mechanism creates performance-enhancing and safety-relevant effects in the bodybuilding context.

In the performance enhancement community, Anadrol occupies a specific and well-defined niche: it is overwhelmingly used as a 4-6 week 'kickstart' at the front of longer injectable cycles, providing rapid strength and size gains during the 3-5 week lag period before testosterone esters reach full plasma concentration. Its short half-life (8-9 hours) makes it pharmacologically suited for this role — it can be cleanly dropped once injectables take over, and PCT can begin just 2-3 days after the last dose.

Clinical data from HIV/AIDS wasting studies confirms the magnitude of its effects: significant lean mass gains, improved functional status, and robust erythropoietic stimulation at therapeutic doses (1-2mg/kg/day). In the performance context, where doses range from 25-100mg/day and are combined with supraphysiological testosterone and other anabolics, effects are more pronounced and side effects considerably more significant.

The compound carries a Black Box FDA warning for hepatotoxicity — cholestatic jaundice, peliosis hepatis, and hepatocellular carcinoma have been documented with long-term use. Despite this, within the performance community, Anadrol's hepatotoxicity is often considered secondary to its blood pressure effects, which practitioners describe as the more immediately dangerous side effect for users who cycle appropriately.

Observed Effects

Anadrol delivers some of the most dramatic anabolic effects of any oral compound available. Strength gains are the most consistently reported and most pronounced effect: bench press increases of 30-50lbs in 4 weeks are frequently documented among experienced users at 50-100mg/day. Squatting 300lbs for the first time or moving from a 315lb to a 385lb squat within 5 weeks are examples drawn from multiple independent first-person accounts. These strength gains are partially attributable to intramuscular water retention and glycogen supercompensation that optimize contractile efficiency, and partially to genuine myofibrillar hypertrophy that persists post-cycle.

Scale weight increases of 18-25lbs over a 4-week cycle are common, though approximately 40-50% of this gain is water weight that departs rapidly post-cycle — many users lose 10-15lbs of water within the first 2 weeks after stopping, sometimes within 72 hours. The lean mass retained post-cycle is typically 10-13lbs from a well-run cycle, consistent with clinical AIDS wasting data showing approximately 50% lean mass retention.

The muscle fullness achieved on Anadrol has a distinct character: intramuscular water (driven by ER agonism and glycogen supercompensation) contributes to a 'pumped even at rest' appearance that experienced users distinguish from the purely subcutaneous bloat seen with excess aromatizable testosterone. This intramuscular component is considered partially beneficial for the aesthetic and performance outcomes during the cycle.

The anabolic response follows a predictable trajectory: noticeable strength and pump improvements begin within 3-7 days of first dose, dramatic effects peak at weeks 2-3, and a characteristic plateau emerges at weeks 4-5 even when the compound is continued. This 'week 4 stagnation' — where the scale stops moving and strength gains halt despite continued dosing — is one of Anadrol's defining characteristics and the mechanistic basis for the 4-6 week cycle cap. Beyond week 4, side effects continue accumulating while anabolic returns diminish.

Erythropoietic stimulation — increased red blood cell production via EPO upregulation — is a documented effect that elevates hematocrit (sometimes to 54-58% versus a normal range of 38-50% in men). While this increases oxygen-carrying capacity, the blood viscosity increase simultaneously elevates cardiovascular risk.

Users running Anadrol alongside potent AR agonists (Trenbolone, Testosterone) consistently report effects beyond what either compound produces alone — reflecting the genuine mechanistic synergy created by Anadrol's non-AR primary anabolic pathway operating alongside AR-mediated compounds.

Field Reports

First-person reports of Anadrol cycles are among the most vivid and consistent in performance enhancement communities, reflecting decades of widespread use and a recognizable signature experience.

The early-cycle window (days 3-14) is described almost universally as remarkable: strength increases appear within 3-5 days, the training pump becomes extreme within 7-10 days, and scale weight begins climbing immediately. The subjective experience is often described as distinct from Dianabol — more 'aggressive' and 'sharp' at 100mg doses, with higher training drive and energy, but also higher anxiety and mood edge compared to Dianabol's more pleasant 'wellbeing' feeling. Many users prefer the 50mg Anadrol experience — strong anabolic effect with a less intense psychological edge.

The debilitating pump phenomenon is the most universally reported negative experience. Back pumps during deadlifts, rows, and squats severe enough to force set termination mid-rep are frequently described. Shin pumps during walking, particularly in the days following leg training, produce a distinct cramping pain. Users who underestimate this side effect are caught off-guard; experienced users pre-load taurine 5-7g/day and manage training around pump sensitivity.

The appetite suppression paradox recurs independently across many accounts: users who started Anadrol expecting to eat everything in sight report instead feeling full, nauseated, and uninterested in food, particularly around dosing time. This is directly counterproductive for bulking cycles that require a significant caloric surplus. a named access routegies that emerge: timing doses after meals rather than before, splitting into small doses, and prioritizing calorie-dense foods that don't require high volume.

The 'week 4 plateau' is one of the most universally acknowledged Anadrol characteristics. Users describe the experience of watching the scale stop, strength stall, and side effects continue — prompting the question of whether to push to 6 weeks. Most experienced users stop at 4-5 weeks, recognizing that the anabolic window has closed and the remaining time only adds cumulative risk.

Post-cycle deflation is rapid and visually dramatic. Users describe 'losing 10lbs of water in 48 hours' and watching the 'pumped' look disappear. This experience is psychologically discouraging for first-time users who expected to retain more. Experienced users frame the water weight as 'scaffolding' — temporary structural support for training volume and intensity that drove real permanent muscle growth underneath.

The 'Anadrol immunity' phenomenon — where a subset of users reports that the compound produces essentially no anabolic response on a second or subsequent cycle — is a distinct and consistent finding across independent sources. While the mechanism is unclear (receptor downregulation, metabolic adaptation, or individual pharmacogenomics), the pattern is notable: first cycle remarkable, subsequent cycle with identical protocol essentially inert. This has practical implications for users considering repeating Anadrol cycles.

Community Consensus

Anadrol occupies a well-defined and respected niche in the oral AAS hierarchy: it is the go-to compound for rapid, dramatic off-season mass accumulation and is ranked among the top two orals (alongside Dianabol) for this purpose by the broader community, with experienced practitioners often ranking it first for sheer mass and strength per week of use.

The Anadrol vs. Dianabol debate has been a defining discourse in performance communities for decades. The community conclusion, hardened over thousands of shared cycles, is nuanced: Dianabol is generally preferred for beginners to oral AAS due to its more forgiving side effect profile and more pleasant subjective experience (described as producing a sense of 'wellbeing and vitality' vs. Anadrol's 'aggressive and stimulated'); Anadrol is preferred by experienced users who want the maximum possible kickstart effect, who are already running potent AR agonists and need a non-redundant mechanism, or who have found Dianabol's aromatization difficult to manage.

The non-AR mechanism that gives Anadrol its special value in multi-drug cycles is well-understood in the advanced community: when already running maximum effective doses of Testosterone and Trenbolone (two potent AR agonists), adding another AR agonist produces diminishing returns. Adding Anadrol instead provides anabolic stimulus through pathways not yet saturated — the combination is additive in a way that additional Testosterone or Trenbolone is not. This is particularly prized in competitive bodybuilding where the goal is to accumulate as much lean mass as possible during the off-season.

The 'kickstart king' designation is the most widely held characterization: Anadrol is considered the optimal kickstart compound due to its fast onset (3-7 days vs. 2+ weeks for injectable esters), dramatic early gains that maintain training intensity during the injectable lag period, and short half-life enabling a clean transition once injectables reach full effect.

Cost considerations shape protocol choices: Anadrol is relatively inexpensive compared to compounds like pharmaceutical-grade peptides or specialty injectables, which makes it accessible to serious users. However, the mandatory support stack (TUDCA, NAC, taurine, bloodwork, BP medication) adds meaningful total cycle cost.

The community is candid about Anadrol being an advanced-only compound — it is consistently discouraged for true beginners not because of cultural gatekeeping but because its side effect management requires experience reading one's body, prior knowledge of personal sensitivities, and comfort with blood monitoring protocols. The risk tolerance required for responsible Anadrol use is substantially higher than for Testosterone-only or Anavar-based protocols.

Risks & Monitoring

Anadrol carries a Black Box FDA warning for hepatotoxicity — the most serious class of warning. The hepatotoxic mechanism is 17α-alkylation: this chemical modification enables oral bioavailability by resisting hepatic first-pass metabolism, but simultaneously concentrates the compound in hepatic tissue. Cholestatic jaundice, peliosis hepatis (blood-filled cysts within the liver), and hepatocellular carcinoma have all been documented with prolonged or repeated Anadrol use. In performance-context bloodwork, ALT/AST elevations of 3-5× above baseline (values of 150-200+ IU/L versus normal <40 IU/L) are typical at 50mg/day; 100mg/day produces approximately 3.4× more ALT elevation than 50mg/day — a disproportionate relationship that underscores the diminishing-returns problem at higher doses. Values exceeding 400 IU/L (>10× normal) have been reported at 100mg/day. Enzyme elevations typically normalize within 4-6 weeks post-cycle, though repeated use without adequate recovery time creates cumulative risk.

Blood pressure elevation is described by experienced practitioners as the most immediately dangerous Anadrol side effect — more acutely threatening than liver enzyme elevation for users who cycle appropriately. The elevation occurs through water retention, increased blood viscosity from polycythemia, and direct hemodynamic effects. Systolic pressures of 150-170+ mmHg during cycles are commonly reported; this level of sustained elevation causes silent left ventricular hypertrophy and arterial stiffening over time. Unlike liver enzymes (which produce detectable symptoms when severely elevated), blood pressure damage accumulates silently.

Estrogenic effects — water retention, gynecomastia risk, mood effects — occur through a mechanism distinct from most anabolic steroids: direct estrogen receptor agonism (particularly ERα) without aromatization. The critical clinical consequence: aromatase inhibitors (anastrozole, exemestane, letrozole) are ineffective against Anadrol's estrogenic effects. Users who crash their estrogen with AIs while on Anadrol still develop gynecomastia and retain water, because these effects are driven by the ER-binding activity of oxymetholone itself, not by elevated estrogen levels. Estrogen receptor modulators (tamoxifen, raloxifene) are the correct management tool — they compete at the ER level rather than suppressing estrogen production.

A 2025 clinical study (n=110) documented a hepatitis incidence of 20.9%, edema incidence of 26.4%, and a 15.5% treatment discontinuation rate. Androgenic side effects were reported in 55.5% of participants. While the clinical population (anemia patients) differs from performance enhancement users, these rates indicate that significant adverse events occur even in monitored therapeutic contexts.

HDL suppression is severe and consistent: multiple users report HDL dropping to 14-25 mg/dL from a baseline of 45-60 mg/dL, representing the most dramatic HDL suppression among commonly used oral AAS. Concurrent LDL elevation creates an atherogenic lipid profile throughout the cycle. This cardiovascular risk accumulates with each additional cycle and is the primary long-term concern for frequent users.

Testosterone suppression is profound and fast: HPG axis suppression of 60-90% of baseline testosterone occurs within the first week of use. Running Anadrol without an exogenous testosterone base results in near-zero endogenous testosterone — severe fatigue, libido loss, and dysfunction. This is why a testosterone base is considered mandatory, not optional.

Back pumps and shin pumps — localized muscle congestion during exercise — range from annoying to debilitating. Multiple users describe pump severity sufficient to terminate training sets, interrupt standing activities, or force exercise modifications. These are among the most consistently reported and complained-about Anadrol side effects across all communities.

Additional commonly reported adverse effects: appetite suppression (paradoxically problematic for bulking, occurring in approximately 30-40% of users), headaches (usually BP-related, often resolving after week 1-2), nosebleeds (BP + polycythemia combination), lethargy in the first week at high doses, and GI irritation that is substantially reduced by always taking with food.

Androgenic side effects (acne, hair loss, prostate irritation) are, counterintuitively, less prominent with Anadrol than with equivalent-dose Testosterone or Trenbolone, despite its DHT-derivative structure. This reflects the fact that Anadrol is not a 5α-reductase substrate and does not amplify into more androgenic metabolites in androgen-sensitive tissues (scalp, prostate, skin). DHT-mediated androgenic effects are therefore more limited than the compound's structural lineage would suggest.

For Women

Monitoring Panels

Avoid With

Protocols By Goal

Off-season mass building (most common use case): Anadrol 50-100mg/day for weeks 1-4 or 1-6, used as a kickstart to a longer injectable cycle.

Backbone: Testosterone Enanthate or Cypionate 400-600mg/week for 12-16 weeks. Optional additions: Deca-Durabolin 300-400mg/week (excellent synergy with Anadrol for mass; note Deca's own suppression and progestogenic considerations) or Nandrolone Phenylpropionate for faster clearance. Dietary approach: high-calorie surplus with controlled sodium (under 2g/day) to limit water retention while maximizing lean mass gain.

Powerlifting pre-meet peak: Anadrol 50-100mg/day for 2-3 weeks before the competition (not 4-6 weeks; shorter run to limit weight class impact). Drop Anadrol 5-7 days before weigh-in to allow partial water clearance while retaining most strength gains (strength gains lag the water by 1-2 weeks). This requires careful calibration — multiple experienced powerlifters describe miscalculating and arriving overweight for their class. Pre-meet sodium restriction in the final 72 hours manages residual water. Testosterone base continues year-round.

Advanced multi-drug cycle (mechanistic synergy): Anadrol 25-50mg/day added to a Testosterone + Trenbolone cycle. Because Anadrol operates primarily through non-AR pathways while Trenbolone is a potent AR agonist, the combination produces additive rather than redundant anabolic effects. The Anadrol dose can be lower (25-50mg) in this context because it's supplementing already-robust anabolic signaling through different pathways, not acting as the primary driver. Often used for 4 weeks to target lagging body parts or break plateau phases during longer cycles.

Weaker body part development: Anadrol's non-AR mechanism makes it particularly effective for driving hypertrophy when AR-mediated pathways are already saturated by other compounds. Experienced competitive bodybuilders target a lagging muscle group (chest thickness, back width, quad sweep) with both increased training volume and Anadrol use during that off-season phase. The non-AR anabolic stimulus provides growth signal that wouldn't come from simply increasing the Testosterone or Trenbolone dose.

Mid-cycle burst (non-kickstart use): Anadrol's fast onset and short half-life allow it to be added at any point in a longer injectable cycle to break a plateau, not only at the beginning. Adding Anadrol at weeks 8-12 of a 16-week injectable cycle delivers a concentrated anabolic pulse when the injectables' marginal effect has plateaued.

Contest prep use (rare, advanced): Some advanced competitive bodybuilders use Anadrol at lower doses (25-50mg/day) during the later phases of contest prep to preserve strength under severe caloric restriction. The water retention is reported to be significantly less when in a caloric deficit vs. a surplus. Still considered high-risk due to BP and liver stress compounding the physiological stress of a deep cut.

Dosing Details

Anadrol's half-life of 8-9 hours means twice-daily dosing (morning and afternoon/evening, with meals) is the standard protocol.

Splitting into 3-4 smaller doses throughout the day with meals is used by some users at 100mg/day to improve GI tolerance and reduce acute appetite suppression.

Dose ranges: - 25mg/day: Test dose for gauging side effect sensitivity; produces modest effects; legitimately used subliminally or as a synergistic add-on at low dose to a full AR-saturated stack - 50mg/day: Community sweet spot; substantial anabolic effect with manageable side effects; roughly 80-90% of the anabolic effect of 100mg with approximately one-third the hepatic stress - 100mg/day: Advanced users only; dramatic strength gains but disproportionately more side effects (BP, pumps, liver enzymes); rarely justified above 100mg given the cost-benefit analysis - Maximum cycle length: 4 weeks for beginners, 6 weeks for experienced users; the characteristic 'week 4 plateau' makes extension beyond 6 weeks both futile and high-risk

Onset and trajectory: Noticeable effects begin within 3-7 days. Peak anabolic response at weeks 2-3. Plateau at weeks 4-5 even with continued dosing.

Dosing timing: Last dose at least 6 hours before sleep (CNS stimulation at 100mg can disrupt sleep); always with food (GI irritation is substantially reduced); pre-workout timing is optional but can exacerbate appetite suppression.

Sublingual administration: Crushing tablets and holding under the tongue for 5-10 minutes before swallowing bypasses much of the first-pass hepatic metabolism, providing higher bioavailability per milligram. Some practitioners use 50mg sublingual 4×/week rather than 50mg/day oral as a harm-reduction strategy. The molecule remains hepatotoxic by this route; acute peak portal blood concentrations are reduced but systemic hepatic processing still occurs.

Mandatory support stack: - Testosterone base: minimum 200mg/week TRT dose; typical cycles use Test E or Test C 400-500mg/week - TUDCA 500mg/day (pre-load 7-10 days before starting, continue 2-4 weeks post-cycle) - NAC 1200-1800mg/day (same timing as TUDCA) - Taurine 3-5g/day for pump management; some users increase to 7-10g pre-workout - Blood pressure monitoring daily for first 2 weeks; telmisartan 20-40mg/day if systolic exceeds 140 mmHg - CBC check at week 2-3; blood donation if hematocrit exceeds 52% - Nolvadex 10-20mg/day or Raloxifene for gynecomastia prevention (NOT an AI)

PCT: Begin 2-3 days after last Anadrol dose (short half-life allows early start). Standard protocol: Clomid 50/50/25/25 + Nolvadex 40/40/20/20 for 4 weeks. If cycle included long-ester injectables, PCT timing is determined by injectable clearance, not Anadrol.

Stacks & Alternatives

Mandatory base. Anadrol suppresses endogenous testosterone 60-90%; exogenous testosterone prevents near-zero T levels, maintains libido, and provides additional anabolic substrate. Test E 400-500mg/week is the standard backbone for Anadrol cycles. The kickstart structure (Anadrol weeks 1-4/6 + Test weeks 1-12+) is the defining Anadrol cycle architecture.

Mechanistic gold-standard stack. Anadrol's non-AR primary mechanism complements Trenbolone's potent AR agonism — two different anabolic pathways firing simultaneously rather than competing at the same receptor. Practitioners consistently describe this as one of the most effective mass-building combinations available, providing additive rather than merely supplemental effects. Advanced users only.

Classic mass-building combination. Deca provides long-duration anabolic support (12-16 week cycles) while Anadrol provides the fast-onset kickstart. Well-documented community reports of 30-35lb gains over 8-week cycles combining both. Requires careful management of Deca's progestogenic and suppressive effects; does not add meaningful hepatotoxicity (Deca is injectable).

Considered the cleanest dual-oral option if a second oral is used during an Anadrol-based cycle. Anavar has a different mechanism and significantly lower hepatotoxicity than Dianabol. The combination provides strength (Anavar excels at strength relative to weight) alongside Anadrol's mass. Cautiously stacked — still two orals simultaneously, and liver monitoring is intensified.

Used on-cycle for gynecomastia prevention/management, not PCT. Because Anadrol's estrogenic effects occur through direct ER binding (not aromatization), only an ER antagonist like Nolvadex or Raloxifene can compete at the receptor level. Nolvadex 10-20mg/day is a standard concurrent preventive measure for gynecomastia-prone users on Anadrol.

Alternatives

Stack Cost

Practical Setup

Monitoring (non-negotiable): Blood pressure should be checked daily during the first two weeks of any Anadrol run.

The silent cardiovascular damage from sustained hypertension is more dangerous long-term than the liver enzyme elevations that get most of the attention. A home blood pressure monitor is essential equipment. Bloodwork (CMP for liver enzymes, CBC for hematocrit) should be obtained before starting and again at weeks 2-3 during the cycle. Post-cycle CMP at 4-6 weeks confirms liver recovery. Without this monitoring, side effect severity cannot be assessed or managed.

Diet matters more than on most compounds: Water retention and blood pressure elevation are substantially modulated by dietary choices. Sodium restriction under 2g/day significantly reduces water accumulation and its associated BP elevation. Users eating clean low-sodium diets while on Anadrol accumulate significantly less water than those eating freely, despite similar anabolic doses. High-carbohydrate eating patterns further exacerbate water retention through insulin-mediated effects. Counterintuitively, some practitioners suggest Anadrol can produce less bloat than equivalent-dose Dianabol for diet-disciplined users, because Anadrol's ER agonism is local while Dianabol drives aromatization that creates systemic estrogen elevation.

Liver protection — specifics matter: Milk thistle is insufficient for 17α-alkylated oral AAS hepatotoxicity. TUDCA 500mg/day is the community standard for meaningful hepatoprotection; NAC 1200-1800mg/day provides glutathione precursor support. Pre-loading both 7-10 days before starting Anadrol is recommended. Concurrent hepatotoxic drugs — acetaminophen, NSAIDs, alcohol — must be eliminated entirely during the run. Users who have access to injectable glutathione describe it as a step above oral protocols for the most aggressive liver support.

The AI mistake: One of the most common expensive mistakes on Anadrol cycles is adding an aromatase inhibitor to control estrogenic effects. AIs are genuinely ineffective against Anadrol's water retention and gynecomastia risk. The correct prevention tools are estrogen receptor modulators: Nolvadex 10-20mg/day or Raloxifene as a preventive measure concurrent with the Anadrol run. Users who simultaneously crash estrogen with AIs can develop the worst of both worlds: all of Anadrol's estrogenic side effects plus the adverse effects of low estrogen (joint pain, libido loss, mood dysregulation).

Hematocrit and blood donation: Hematocrit above 52% (a common outcome on Anadrol cycles) significantly increases blood viscosity and stroke/clot risk. A single blood donation (approximately 470ml) typically drops hematocrit 3-4 points within 48 hours. This is a practical, accessible intervention that many experienced AAS users schedule proactively. Some blood donation centers require honesty about steroid use, which limits access; therapeutic phlebotomy via a physician is an alternative for those who disclose.

The 'Anadrol immunity' risk: A subset of users reports complete loss of anabolic response on second or subsequent Anadrol cycles. This is distinct from diminishing returns (which affect everyone) and represents a genuine concern for users planning repeat cycles. Whether this reflects receptor downregulation, metabolic adaptation, or individual pharmacogenomics is unknown. Practical implication: treat each Anadrol run as potentially a limited resource — use it for the highest-priority cycle, not routinely.

Stacking logic: The most common expensive mistake in Anadrol stacking is adding Dianabol simultaneously — two hepatotoxic orals with partially overlapping mechanisms. The correct add-on logic: if a second oral is used, choose Anavar (lower hepatotoxicity, different mechanism). If adding a non-oral compound for synergy, choose Trenbolone (non-AR mechanism complement). Anadrol's value is maximized when it operates as the mechanistically distinct agent in a cycle, not when stacked with mechanistically similar compounds.

Mechanism Deep Dive

Oxymetholone's pharmacology is multifactorial and, in several respects, genuinely unusual among anabolic-androgenic steroids — the combination of mechanisms accounts for its distinct clinical profile and its unique role in performance stacking.

Non-androgen-receptor primary anabolic mechanism: The most important mechanistic distinction is that Anadrol's primary anabolic action does not appear to be mediated primarily through the androgen receptor. Evidence for this includes: (1) Anadrol retains significant anabolic activity in assays where AR signaling is fully blocked; (2) it produces anabolic effects additive to maximal AR agonism rather than competitive with it; (3) its anabolic:androgenic ratio (approximately 320:45 relative to testosterone's 100:100) implies strong anabolic effects through pathways that are not androgen-receptor-dependent. The actual non-AR mechanisms are incompletely characterized but likely involve prostaglandin biosynthesis modulation, possible eIF-4E-mediated translational efficiency enhancement, and effects on satellite cell signaling.

Estrogen receptor agonism (not aromatization): Despite its DHT-derived structure, oxymetholone acts as a direct agonist at the estrogen receptor (particularly ERα) without requiring enzymatic conversion via aromatase. This mechanism explains the compound's estrogenic profile — water retention, gynecomastia risk, mood effects — in the absence of measurable estrogen elevation. The critical practical consequence: aromatase inhibitors (which block estrogen synthesis) are ineffective against these effects. Only estrogen receptor modulators (tamoxifen, raloxifene) that compete at the ER level provide protection. This is a clinically confirmed distinction confirmed by cell-culture assays showing Anadrol's estrogenic activity is resistant to anastrozole but blocked by tamoxifen.

17α-methylation and hepatotoxicity: The 17α-methyl group enables oral bioavailability by resisting hepatic first-pass metabolism. The same modification concentrates the compound in liver tissue, driving cholestatic hepatotoxicity, ALT/AST elevation, and, with prolonged use, the severe structural hepatic injuries documented in the Black Box warning (peliosis hepatis, hepatocellular carcinoma). The dose-dependent relationship — 100mg producing 3.4× more ALT elevation than 50mg — reflects the saturation of hepatic processing capacity.

DHT-derivative structure and the 5α-reductase paradox: As a DHT-derived compound, Anadrol might be expected to have high androgenic potency in DHT-sensitive tissues (scalp, skin, prostate). However, Anadrol is NOT a substrate for 5α-reductase — the enzyme that converts testosterone to the more potent DHT, and which similarly amplifies other DHT precursors in androgen-sensitive tissues. Because oxymetholone cannot be further reduced in these tissues, its androgenic impact in scalp, skin, and prostate is substantially lower than its DHT-derivative status would predict. The 5α-reductase inhibitors (finasteride, dutasteride) that protect against testosterone-induced hair loss offer limited benefit against Anadrol for the same reason.

Mestanolone metabolite: Oxymetholone is metabolized to mestanolone (17α-methyl-5α-dihydrotestosterone), which has an androgenic rating of approximately 1400 relative to testosterone — far higher than the parent compound's rating of 45. However, conversion to this metabolite is limited and tissue-distribution-dependent. The net androgenic effect is therefore moderate despite the high potency of the metabolite, explaining the modest-but-real androgenic activity of Anadrol that doesn't fully reflect its DHT-derivative structure.

Erythropoietic stimulation: Oxymetholone stimulates renal erythropoietin (EPO) production, which in turn drives red blood cell production in the bone marrow. This was the basis for its original FDA indication (aplastic anemia). In the performance context, elevated EPO leads to increased RBC count, hemoglobin, and hematocrit — improving oxygen-carrying capacity while also increasing blood viscosity and cardiovascular thrombotic risk. The compound's nitrogen balance and protein synthesis effects add to its anabolic profile but are secondary to the mechanisms above in explaining its distinctive profile.

Evidence Index